GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (FRA:7EY) » Definitions » Other Long-Term Liabilities

Kiora Pharmaceuticals (FRA:7EY) Other Long-Term Liabilities : €4.87 Mil (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kiora Pharmaceuticals Other Long-Term Liabilities?

Kiora Pharmaceuticals's other long-term liabilities for the quarter that ended in Jun. 2024 was €4.87 Mil.

Kiora Pharmaceuticals's quarterly other long-term liabilities increased from Dec. 2023 (€4.70 Mil) to Mar. 2024 (€4.71 Mil) and increased from Mar. 2024 (€4.71 Mil) to Jun. 2024 (€4.87 Mil).

Kiora Pharmaceuticals's annual other long-term liabilities increased from Dec. 2021 (€2.70 Mil) to Dec. 2022 (€3.13 Mil) and increased from Dec. 2022 (€3.13 Mil) to Dec. 2023 (€4.70 Mil).

Kiora Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for Kiora Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Other Long-Term Liabilities Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kiora Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kiora Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Kiora Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiora Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (FRA:7EY) » Definitions » Other Long-Term Liabilities
Comparable Companies
APTX RNAZ ENDV AXIM IPIX SILO ZVSA ZIVO CPMV NEXI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KPRX:USA
Address
332 Encinitas Boulevard, Suite 102, Encinitas, CA, USA, 92024
Website
https://www.kiorapharma.com
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Kiora Pharmaceuticals Headlines

No Headlines